ImmunoPET Imaging of TIM‐3 in Murine Melanoma Models
- 17 April 2020
- journal article
- research article
- Published by Wiley in Advanced Therapeutics
- Vol. 3 (7) , 2000018
Abstract
T cell immunoglobulin and mucin domain‐containing‐3 (TIM‐3) is an immune checkpoint expressed mainly on CD4+ and CD8+ T cells. In addition to negatively regulating inflammatory T cell function, TIM‐3 is a promising immunotherapy target. Herein, the aim is to develop an immuno‐positron emission tomography (immunoPET) probe for noninvasively characterizing TIM‐3 expression. Flow cytometry is used to detect the expression levels of TIM‐3 in B16F10 cells. RMT3‐23, a rat antimouse TIM‐3‐specific monoclonal antibody, is radiolabeled with 64Cu and the performance of 64Cu‐NOTA‐RMT3‐23 is interrogated by immunoPET in murine melanoma models before and after radiation therapies. Biodistribution and immunofluorescent staining studies are carried out after the immunoPET imaging studies. TIM‐3 is negatively expressed in B16F10 cells, and its expression is not induced by radiation therapies. ImmunoPET imaging with 64Cu‐NOTA‐RMT3‐23 precisely tracks the unique distribution of TIM‐3‐positive lymphocytes in immunocompetent melanoma models, and tumor uptake of the radiotracer is not affected by either single‐dose or fractionated radiation therapies. The 64Cu‐NOTA‐RMT3‐23 immunoPET imaging results are further mirrored by the immunofluorescent staining studies. These results demonstrate the feasibility of 64Cu‐NOTA‐RMT3‐23 immunoPET in tracking TIM‐3 and highlight a new opportunity to optimize TIM‐3‐targeted immunotherapies with this novel imaging strategy.Keywords
Funding Information
- National Institutes of Health (P30CA014520)
- National Natural Science Foundation of China (81771858)
This publication has 43 references indexed in Scilit:
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014
- Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodiesJournal of Experimental Medicine, 2013
- Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T CellsCancer Immunology Research, 2013
- Anti-TIM3 Antibody Promotes T Cell IFN-γ–Mediated Antitumor Immunity and Suppresses Established TumorsCancer Research, 2011
- Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemiaBlood, 2011
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunityJournal of Experimental Medicine, 2010
- Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 AntibodyClinical Cancer Research, 2009
- TIM-3 Is Expressed in Melanoma Cells and Is Upregulated in TGF-Beta Stimulated Mast CellsJournal of Investigative Dermatology, 2007
- Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune diseaseNature, 2002
- CTLA-4-Mediated Inhibition in Regulation of T Cell Responses: Mechanisms and Manipulation in Tumor ImmunotherapyAnnual Review of Immunology, 2001